Detailed view for LOAG_08113

Basic information

TDR Targets ID: 941794
Loa Loa (eye worm), plk/plk-unclassified protein kinase

Source Database / ID:  KEGG  

pI: 7.8173 | Length (AA): 546 | MW (Da): 61199 | Paralog Number: 5807

Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0

Druggability Group : DG2

Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable

Pfam domains

PF00069   Protein kinase domain

Gene Ontology

Mouse over links to read term descriptions.
GO:0005524   ATP binding  
GO:0005515   protein binding  
GO:0004672   protein kinase activity  
GO:0006468   protein amino acid phosphorylation  

Metabolic Pathways

Structural information

Modbase 3D models:

There are 10 models calculated for this protein. More info on these models, including the models themselves is available at: Modbase

Target Beg Target End Template Template Beg Template End Identity Evalue Model Score MPQS zDope
4 365 5ncl (A) 312 756 23.00 0 1 0.768904 0.54
9 349 4wih (A) 4 347 28.00 0 1 0.964442 -0.3
9 360 3uto (A) 121 467 24.00 0 1 0.962589 -0.28
28 323 2rku (A) 37 326 42.00 0 1 1.08302 -0.61
43 444 5t6a (A) 50 475 25.00 0 1 0.994064 0.05
49 307 5ig1 (A) 23 281 33.00 0 1 0.932259 -0.78
359 539 4o9w (A) 374 594 27.00 0 1 0.411402 -0.4
361 530 4rs6 (A) 470 680 30.00 0 1 0.435255 -0.34
368 516 4rs6 (A) 477 665 36.00 0.0000045 0.48 0.227194 0.68
377 535 4j7b (B) 388 583 29.00 0 1 0.457109 -0.46

Help me make sense of these data.

Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)

A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.

PDB Structures:

No structure availble in the PDB for this protein

Expression

No expression data available for this gene

Orthologs

This protein does not belong to any OrthoMCL cluster.

Essentiality

No essentiality data collected for this gene and/or its orthologs.

Phenotypes and Validation (curated)

We have no manually annotated phenotypes for this target. What does this mean? / Care to help?

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.

In any case, if you have information about papers containing relevant validation data for this target, please contact us.


Annotated validation

No validation data for this target

Associated compounds / Druggability

Known modulators for this target

No chemical compounds associated to this gene

Predicted associations

By orthology with druggable targets
Non orthologous druggable targets
By sequence similarity to non orthologous druggable targets
Species Target Length Identity Alignment span Linked Drugs Reference
Oryctolagus cuniculus cAMP-dependent protein kinase alpha-catalytic subunit 351 aa 29.7% 293 aa Compounds References
Sus scrofa Casein kinase I isoform alpha 125 aa 31.1% 132 aa Compounds References
Rattus norvegicus cAMP-dependent protein kinase alpha-catalytic subunit 351 aa 31.3% 300 aa Compounds References
Plasmodium falciparum (isolate 3D7) Cell division control protein 2 homolog 288 aa 27.3% 286 aa Compounds References
Rattus norvegicus Cell division protein kinase 5 292 aa 25.6% 285 aa Compounds References
Bos taurus cAMP-dependent protein kinase alpha-catalytic subunit 351 aa 31.4% 293 aa Compounds References
Patiria pectinifera Cdc2 300 aa 27.7% 289 aa Compounds References
Rattus norvegicus Mitogen-activated protein kinase 1 358 aa 27.3% 311 aa Compounds References
Oryctolagus cuniculus Cyclin-dependent kinase 4 189 aa 33.1% 154 aa Compounds References
Homo sapiens Cyclin-dependent kinase 1/cyclin B1 297 aa 28.5% 291 aa Compounds References

Obtained from network model

Ranking Plot


Putative Drugs List


Compound Raw Global Species
0.0032 0.5 0.5
0.0061 0.6883 0.6883
0.0042 0.5 0.5
0.0064 0.3377 0.3377
0.0004 0.5 0.5
0.0036 0.5 0.5
0.0059 1 1
0.0003 0.5 0.5
0.0039 0.9485 1
0.0007 0.5 0.5
0.0033 1 1
0.0032 0.5 0.5
0.0062 0.6935 0.6935
0.0063 1 1
0.0007 0.5 0.5
0.0023 0.5 0.5
0.0063 0.7244 0.6686
0.0007 0.5 0.5
0.0092 1 1
0.0039 0.5 0.5
0.0008 0.5 0.5
0.0011 1 1
0.0066 0.3101 0.3068
0.0033 0.5 0.5
0.0029 0.5 0.5
0.0039 0.5 0.5
0.0037 1 0.5
0.0056 1 1
0.0026 0.5 0.5
0.0069 0.3067 0.9179
0.0098 0.3242 0.3017
0.0012 0.5 0.5
0.0016 0.5 0.5
0.0081 0.5 0.5
0.0016 0.5 0.5
0.0027 1 1
0.0012 0.5 0.5
0.0059 1 1
0.0091 1 1
0.0067 0.5 0.5
0.0088 0.4477 0.4477
0.0018 0.5 0.5
0.0059 1 1
0.0081 1 1
0.0022 0.5 0.5
0.0012 0.5 0.5
0.0093 0.8828 0.8828

Assayability

Assay information

No assay information for this target.

Reagent availability

No reagent availability information for this target.

Bibliographic References

No literature references available for this target.

If you have references for this gene, please enter them in a user comment (below) or Contact us.

User comments

No user comments are available for this gene. Log in to add comments, or register.

Enter your comment

User ()
Gene identifier LOAG_08113 (Loa Loa (eye worm)), plk/plk-unclassified protein kinase
Title for this comment
Comment